Monthly Prescribing Reference1 日
BrainsWay Deep TMS Device Cleared for Older Patients With MDD
Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain. The Food and Drug Administration (FDA) has expanded the ...
Monthly Prescribing Reference1 日
FDA Approves First Generics of Heart Failure Combo Drug Entresto
The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and Drug Administration (FDA) has approved the first generics of Entresto ® ...
Monthly Prescribing Reference1 日
Boehringer Ingelheim Caps Asthma, COPD Inhalers at $35 Per Month for Eligible Patients
The program automatically reduces the cost of the inhaler at the pharmacy for eligible patients with commercial insurance. Out-of-pocket costs for Boehringer Ingelheim asthma and chronic obstructive ...
Monthly Prescribing Reference1 日
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
Authors found that BMI of 27 or greater shows excellent diagnostic performance. HealthDay News — The optimal body mass index (BMI) cutoff point appears to be 27kg/m 2 for detecting obesity in ...
Monthly Prescribing Reference1 日
Weight Navigation Program Boosts Use of Weight Management Treatments
Greater use of weight management treatments seen with WNP, including bariatric surgery, low-calorie meal replacement. HealthDay News — A primary care-based weight navigation program (WNP) is feasible ...
Monthly Prescribing Reference1 日
Plozasiran Significantly Cuts Triglycerides in Familial Chylomicronemia Syndrome
Findings showed patients treated with plozasiran 25mg and 50mg had median triglyceride reductions of -80% and -78%, respectively, compared with -17% for placebo. Plozasiran significantly reduced ...
Monthly Prescribing Reference1 日
Mitapivat Beneficial in Transfusion-Dependent Alpha- or Beta-Thalassemia
Results showed 30.4% of patients treated with mitapivat achieved a transfusion reduction response vs 12.6% of patients who received placebo. Mitapivat was associated with a significant reduction in ...
Monthly Prescribing Reference4 日
FDA Approves mRNA-Based RSV Vaccine mResvia
Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 years of age and older. The Food and Drug Administration (FDA) has ...
Monthly Prescribing Reference5 日
Retevmo Approved for Younger Patients With RET-Driven Thyroid Cancer, Solid Tumors
Results from LIBRETTO-121 showed a confirmed overall response rate of 48% (95% CI, 28-69). The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the ...
Monthly Prescribing Reference4 日
CDC Reports Third Dairy Worker Infected With Bird Flu, Risk to Public Remains ‘Low’
The CDC is monitoring influenza activity closely in states affected by the H5N1 outbreak and said there's been "no sign of unusual influenza activity." HealthDay News — Amid an ongoing outbreak of ...
Monthly Prescribing Reference7 日
Brensocatib Reduces the Rate of Pulmonary Exacerbations in Bronchiectasis
Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in patients ...
Monthly Prescribing Reference4 日
FDA Extends Review Period for Dupilumab in COPD With Type 2 Inflammation
The additional information provided by Regeneron and Sanofi was considered a major amendment to the application. The Food and Drug Administration (FDA) has extended the review period for the ...